Sophiris is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company is currently developing PRX302 for the treatment of BPH symptoms which is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments.
|HQ||San Diego, US||Map|
|Employees (est.) (Dec 2018)||6|
|Share Price (Jun 2019)||$0.8|
Net income (FY, 2018)
Market capitalization (10-Jun-2019)
Closing stock price (10-Jun-2019)
|USD||Q2, 2014||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q1, 2018||Q2, 2018|
Depreciation and Amortization
Cash From Operating Activities
Sophiris has 152 Twitter Followers. The number of followers has increased 3.4% month over month and increased 9.6% quarter over quarter
When was Sophiris founded?
Sophiris was founded in 2002.
How many employees does Sophiris have?
Sophiris has 6 employees.
Who are Sophiris competitors?
Competitors of Sophiris include Cantabio Pharmaceuticals, Roche and Bristol-Myers Squibb.
Where is Sophiris headquarters?
Sophiris headquarters is located at 1258 Prospect St, La Jolla, San Diego.
Where are Sophiris offices?
Sophiris has an office in San Diego.
How many offices does Sophiris have?
Sophiris has 1 office.
Receive alerts for 300+ data fields across thousands of companies